thalidomide has been researched along with Mucositis, Oral in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter clinical trial was designed to evaluate the efficacy and safety of thalidomide (THD) in preventing oral mucositis (OM) in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT)." | 9.51 | Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial. ( Hu, K; Jiang, L; Liang, L; Lin, Z; Liu, Z; Ning, X; Shi, Z; Wang, H; Wang, R; Wei, Y; Yan, H; Zhu, H, 2022) |
| "This multicenter clinical trial was designed to evaluate the efficacy and safety of thalidomide (THD) in preventing oral mucositis (OM) in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT)." | 5.51 | Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial. ( Hu, K; Jiang, L; Liang, L; Lin, Z; Liu, Z; Ning, X; Shi, Z; Wang, H; Wang, R; Wei, Y; Yan, H; Zhu, H, 2022) |
| "Crohn's disease is a chronic inflammatory disease, which may involve any part of the gastrointestinal tract, including the oral cavity." | 2.41 | [Oral aspects of Crohn's disease]. ( Brand, HS; Scheper, HJ, 2000) |
| "Oral mucositis is the most common oral complication of cancer patients receiving radiotherapy or chemotherapy, leading to poor quality of life." | 1.72 | Thalidomide attenuates oral epithelial cell apoptosis and pro-inflammatory cytokines secretion induced by radiotherapy via the miR-9-3p/NFATC2/NF-κB axis. ( Chen, J; Chen, L; Jiang, L; Liang, L; Liu, G; Que, L; Wang, R; Zhu, H, 2022) |
| "Thalidomide treatment demonstrated a significant mucositis-ameliorating effect during fractionated irradiation, which is likely to result from NF-κB inhibition." | 1.43 | Modulation of radiation-induced oral mucositis by thalidomide : Preclinical studies. ( Dörr, W; Frings, K; Gruber, S; Kleiter, M; Kuess, P, 2016) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, L | 2 |
| Liu, Z | 1 |
| Zhu, H | 2 |
| Wang, H | 1 |
| Wei, Y | 1 |
| Ning, X | 1 |
| Shi, Z | 1 |
| Jiang, L | 2 |
| Lin, Z | 1 |
| Yan, H | 1 |
| Wang, R | 2 |
| Hu, K | 1 |
| Chen, L | 1 |
| Liu, G | 1 |
| Que, L | 1 |
| Chen, J | 1 |
| Mahé, E | 1 |
| Frings, K | 1 |
| Gruber, S | 1 |
| Kuess, P | 1 |
| Kleiter, M | 1 |
| Dörr, W | 1 |
| Addie, DD | 1 |
| Radford, A | 1 |
| Yam, PS | 1 |
| Taylor, DJ | 1 |
| Lima, V | 1 |
| Brito, GA | 1 |
| Cunha, FQ | 1 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Ribeiro, RA | 1 |
| Scheper, HJ | 1 |
| Brand, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Immunonutrients in Reducing Oral Mucositis in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective, Multicenter, Randomized Controlled Clinical Trial[NCT05892354] | 190 participants (Anticipated) | Interventional | 2023-06-10 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Mucositis, Oral
| Article | Year |
|---|---|
[Oral aspects of Crohn's disease].
Topics: Crohn Disease; Dental Caries; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; O | 2000 |
1 trial available for thalidomide and Mucositis, Oral
| Article | Year |
|---|---|
Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Humans; Nasopharyngeal | 2022 |
5 other studies available for thalidomide and Mucositis, Oral
| Article | Year |
|---|---|
Thalidomide attenuates oral epithelial cell apoptosis and pro-inflammatory cytokines secretion induced by radiotherapy via the miR-9-3p/NFATC2/NF-κB axis.
Topics: Animals; Apoptosis; Cytokines; Epithelial Cells; Humans; Mice; MicroRNAs; NF-kappa B; NFATC Transcri | 2022 |
Everolimus-induced aphthous stomatitis controlled by apremilast in a heart-transplant patient.
Topics: Antineoplastic Agents; Everolimus; Humans; Stomatitis; Stomatitis, Aphthous; Thalidomide | 2023 |
Modulation of radiation-induced oral mucositis by thalidomide : Preclinical studies.
Topics: Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Immunosuppressive | 2016 |
Cessation of feline calicivirus shedding coincident with resolution of chronic gingivostomatitis in a cat.
Topics: Administration, Oral; Administration, Topical; Animals; Calicivirus, Feline; Cat Diseases; Cats; Chr | 2003 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |